AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of Andrew Lane as an independent non-executive director.

The appointment fills the vacancy left by Jon Lamb who retires from the board today following his 11-year tenure.

Chair David Flacks says: “We are delighted to welcome Andrew to our board. He has outstanding experience as a senior business executive in international growth markets, having most recently led Abbott Laboratories Pharmaceutical Division with turnover growing from NZ$4 Bil to over NZ$9 Bil during his tenure.

“This unique experience is highly relevant to AFT as we grow and consolidate our position in Australasia and build our presence internationally with our Maxigesic® pain relief and other medications.”

Andrew says: “I am excited by the opportunity to assist AFT with its growth aspirations and will be using my accumulated knowledge in finance, sales and marketing within general, regional and global management for this.”

The board has determined that Andrew Lane is an Independent Director (within the meaning of the NZX Listing Rules).

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.